These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27441206)

  • 1. Adoptive Transfer of Myeloid-Derived Suppressor Cells and T Cells in a Prostate Cancer Model.
    Yan L; Xu Y
    Bio Protoc; 2015 Aug; 5(16):. PubMed ID: 27441206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of OGR1 in myeloid-derived cells in prostate cancer.
    Yan L; Singh LS; Zhang L; Xu Y
    Oncogene; 2014 Jan; 33(2):157-64. PubMed ID: 23222714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.
    Jachetti E; Cancila V; Rigoni A; Bongiovanni L; Cappetti B; Belmonte B; Enriquez C; Casalini P; Ostano P; Frossi B; Sangaletti S; Chiodoni C; Chiorino G; Pucillo CE; Tripodo C; Colombo MP
    Cancer Immunol Res; 2018 May; 6(5):552-565. PubMed ID: 29523597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
    Jain AK; Raina K; Agarwal R
    Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection.
    Drujont L; Carretero-Iglesia L; Bouchet-Delbos L; Beriou G; Merieau E; Hill M; Delneste Y; Cuturi MC; Louvet C
    PLoS One; 2014; 9(6):e100013. PubMed ID: 24927018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
    Jenq RR; Curran MA; Goldberg GL; Liu C; Allison JP; van den Brink MR
    PLoS One; 2012; 7(4):e35222. PubMed ID: 22493742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.
    Williams TM; Hassan GS; Li J; Cohen AW; Medina F; Frank PG; Pestell RG; Di Vizio D; Loda M; Lisanti MP
    J Biol Chem; 2005 Jul; 280(26):25134-45. PubMed ID: 15802273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
    Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
    Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
    Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
    Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
    Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
    Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
    J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.
    Morales JK; Kmieciak M; Knutson KL; Bear HD; Manjili MH
    Breast Cancer Res Treat; 2010 Aug; 123(1):39-49. PubMed ID: 19898981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
    Dzojic H; Loskog A; Tötterman TH; Essand M
    Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer.
    Haughey CM; Mukherjee D; Steele RE; Popple A; Dura-Perez L; Pickard A; Patel M; Jain S; Mullan PB; Williams R; Oliveira P; Buckley NE; Honeychurch J; S McDade S; Illidge T; Mills IG; Eddie SL
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.